



Metastatic Castration-Resistant Prostate Cancer (mCRPC):

Therapeutic Advances and Strategies Throughout the Course of Care

Once a patient has developed metastatic castration-resistant prostate cancer, many complex factors come into play that determine which therapies come next and in what order, including someone's disease and treatment history, medication toxicities, and genomic and biomarker profiles.


Matthew Zibelman, MD, Associate Professor, Department of Hematology/Oncology and Director of Clinical and Translational Research for the GU Service Line at Fox Chase Cancer Center,



Zibelman

said, "An academic center like Fox Chase known for its prostate cancer care ensures that the individual receives the latest optimal therapies for the current stage of their disease, including the most recent radioligand therapy, chemotherapy, alternate targeted oral therapies, and clinical trials."

"A great strength at Fox Chase is that our multidisciplinary team quickly develops a patient-centered care plan that encompasses an individual's specific needs—for an optimal outcome with the fewest possible side effects."



FoxChase.org

Watch Now:

Dr. Zibelman discusses the latest optimal therapies and strategies for managing mCRPC, including the most recent radioligand therapy, chemotherapy, alternate targeted oral therapies, and clinical trials.



2025 Practice-Changing Updates in Bladder, Kidney & Prostate Cancers THURSDAY, OCTOBER 23, 2025

Updates in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Matthew R. Zibelman, MD
Associate Professor, Department of Hematology/Oncology,
Division of Genitourinary Medical Oncology,
Director of Clinical and Translational Research, GU Service Line



Fox Chase Cancer Center Temple Health

The Right mCRPC Therapies at the Right Time

Breakthrough PLUVICTO® Radioligand Therapy

Now, patients who are PSMA-positive (prostate-specific membrane antigen positive)*, can receive the breakthrough radioligand PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan) pre-chemotherapy, adding another viable window of opportunity to treat the disease.

Lutetium therapy is standard of care for patients with metastatic castrate-resistant prostate cancer whose cancer is PSMA-positive on PET scan either pre- or post-chemotherapy.

*PSMA PET scan from referrer or Fox Chase

Therapies for Every Point Along the Treatment Continuum

- **Radioligand pharmaceuticals** help to improve symptoms and extend life.
- **Targeted agents including FDA-approved PARP inhibitors**, which target specific genetic mutations like BRCA in mCRPC patients previously treated with androgen receptor-directed therapy.
- **Immunotherapies** such as checkpoint inhibitors for eligible patients.
- **Adaptive SBRT** reduces tumor burden and may ameliorate pain or prolong time to next systemic therapy using better tumor targeting and minimizing side effects by sparing healthy tissue.
- **Chemotherapy** options include docetaxel-based regimens, which improve survival and provide palliative relief.

Promising Clinical Trials for mCRPC

Fox Chase actively studies, develops, and evaluates new therapies for mCRPC, often before they are available elsewhere. Our robust clinical trials portfolio includes:

- Novel targeted hormonal therapies
- Bispecifics
- Novel targeted radioligand therapies
- Antibody drug conjugates

How to Refer

To refer a patient to our program, please call **888-FOX-CHASE (888-369-2427)** or visit **FoxChase.org/Refer**.



On behalf of all of us, thank you for your referrals. We look forward to working as part of your team.

Contact Our Team

Our Key Account Managers can offer a seamless introduction to our specialists, obtain a patient appointment, and answer any questions or concerns you have. Contact our team at **KeyAccountManager@FCCC.edu**.

Why Choose Fox Chase?

- Fox Chase is a National Cancer Institute (NCI) Comprehensive Cancer Center: the highest NCI designation for excellence in cancer treatment, research, prevention, and education.
- Fox Chase is distinguished regionally as a founding member of the National Comprehensive Cancer Network® (NCCN), a not-for-profit alliance of leading cancer centers. Our faculty members participate in cancer panels at the NCCN, helping to write the guidelines for cancer care that inform clinical decisions in medical centers across the country.
- Fox Chase is nationally ranked by *U.S. News & World Report* as 18 among the nation's top hospitals for urologic cancer care, as a High Performing hospital for Prostate Cancer Surgery, and as a High Performing National Leader in Cancer.
- Fox Chase Cancer Center has been designated Philadelphia's First Comprehensive Radiopharmaceutical Therapy Center of Excellence by the Society of Nuclear Medicine & Molecular Imaging, offering the highest level of care from the world's best-trained clinicians.
- *Philadelphia* magazine consistently rates specialists from Fox Chase Cancer Center and Fox Chase – Temple Urologic Institute as Top Doctors® in urologic oncology and GU cancer.

Non-discrimination notice: It is the policy of Fox Chase Cancer Center and Temple University Hospital, Inc., that no one shall be excluded from or denied the benefits of or participation in the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

© Fox Chase Cancer Center. All rights reserved. 2/26